Brief: Cyteir Therapeutics Announces Prioritization Of CYT-0851 Development
19/01/2023 21:41
Jan 19 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* CYTEIR THERAPEUTICS ANNOUNCES PRIORITIZATION OF CYT-0851
DEVELOPMENT AND EXTENDED CASH RUNWAY
* CYTEIR THERAPEUTICS INC - ENCOURAGING EARLY CLINICAL
RESULTS
OBSERVED IN TREATING OVARIAN CANCER WITH CYT-0851 COMBINATION
THERAPY
* CYTEIR THERAPEUTICS INC - EXPECTED TO EXTEND CASH RUNWAY
INTO
2026
* CYTEIR THERAPEUTICS INC - REDUCING HEADCOUNT BY
APPROXIMATELY
70%
* CYTEIR THERAPEUTICS INC - DEFERRING RESEARCH AND
DEVELOPMENT IN
AREAS OTHER THAN OVARIAN CANCER
* CYTEIR THERAPEUTICS INC - WILL BE SUSPENDING ALL
PRECLINICAL
RESEARCH
* CYTEIR THERAPEUTICS INC - ESTIMATES THAT IT WILL INCUR
AGGREGATE
CHARGES OF APPROXIMATELY $2.5 MILLION TO $3 MILLION
* CYTEIR THERAPEUTICS INC - MAJORITY OF CHARGES ARE EXPECTED
TO BE
INCURRED IN Q1 OF 2023
Source text for Eikon: ID:nBwf93Qda
Further company coverage: CYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile